Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials

References

• Malik SM, Maher VE, Bijwaard KE, et al. U.S. food and drug administration approval: crizotinib for treatment of advanced or metastatic non–small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20(8):2029–2034.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2015;21:2436–2439.
   PubMed Web of Science ®Google Scholar
• Larkins E, Blumenthal GM, Chen H, et al. FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22:5171–5176.
   PubMed Web of Science ®Google Scholar
• Markham A. Brigatinib: first global approval. Drugs. 2017;77:1131–1135.
   PubMed Web of Science ®Google Scholar
• Syed YY. Lorlatinib: first global approval. Drugs. 2019;79:93–98.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Maione P, et al. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2018;18:71–80.
   PubMed Web of Science ®Google Scholar
• Chuang C-H, Chen H-L, Chang H-M, et al. Systematic review and network meta-analysis of Anaplastic Lymphoma Kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer. Cancers (Basel). 2021;13(8):1966.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. 2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. cited 2021 Oct 29
   Google Scholar
• Khan M, Lin J, Liao G, et al. ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2018;8:557.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Tang Y, Polli A, et al. Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med. 2016;5(4):617–622.
   PubMed Web of Science ®Google Scholar
• Morcos PN, Bogman K, Hubeaux S, et al. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemother Pharmacol. 2017;79:559–568.
   PubMed Web of Science ®Google Scholar
• Girard N, Audigier-Valette C, Cortot AB, et al. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice? Expert Rev Anticancer Ther. 2015;15:225–233.
   PubMed Web of Science ®Google Scholar
• Cirne F, Zhou S, Kappel C, et al. ALK inhibitor-induced bradycardia: a systematic-review and meta-analysis. Lung Cancer. 2021;161:9–17.
   PubMed Web of Science ®Google Scholar
• Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029–2039 .
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen C, Rong C, et al. Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: a recent five-year pharmacovigilance study. Front Pharmacol. 2022;13:858279 .
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Leiva O, Dagogo-Jack I, et al. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J Thorac Oncol. 2020;15:1497–1506.
   PubMed Web of Science ®Google Scholar
• Pérez-Callejo D, Torrente M, Brenes MA, et al. Lung cancer as a cardiotoxic state: a review. Med Oncol. 2017;34:159.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Label of crizotinib (PDF). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s031lbl.pdf. Cited 2021 Sep 22
   Google Scholar
• U.S. Food and Drug Administration. Label of ceritinib (PDF). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205755s019lbl.pdf. Cited 2021 Oct 7
   Google Scholar
• U.S. Food and Drug Administration. Label of alectinib (PDF). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf Cited 2021 Sep 3
   Google Scholar
• U.S. Food and Drug Administration. Label of brigatinib (PDF). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208772s012lbl.pdf. Cited 2021 Sep 24
   Google Scholar
• U.S. Food and Drug Administration. Label of lorlatinib (PDF). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf. Cited 2021 Mar 3
   Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Kim D-W, Wu Y-L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018;36:2251–2258.
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Lu S, Lu Y, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018;13:1539–1548.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917–929.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874–886.
   PubMed Web of Science ®Google Scholar
• Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409–1416.
   PubMed Web of Science ®Google Scholar
• Zhou C, Kim S-W, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7:437–446.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–838.
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29–39.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38:3592–3603.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced -positive lung cancer. N Engl J Med. 2020;383:2018–2029.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Tong WP, Azada M, et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer. 2013;119:1969–1975.
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38:693–710 .
   PubMed Web of Science ®Google Scholar
• Fukuizumi A, Miyanaga A, Seike M, et al. Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report. BMC Res Notes. 2015;8:165.
   PubMedGoogle Scholar
• Zhu VW, Zhao JJ, Gao Y, et al. Thromboembolism in ALK+ and ROS1+ NSCLC patients: a systematic review and meta-analysis. Lung Cancer. 2021;157:147–155 .
   PubMed Web of Science ®Google Scholar
• Zer A, Moskovitz M, Hwang DM, et al. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer. 2017;18:156–161.
   PubMed Web of Science ®Google Scholar
• Alexander M, Solomon B, Burbury K. Thromboembolism in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Lung Cancer. 2018;19:e71–e72.
   PubMed Web of Science ®Google Scholar
• Nichetti F, Lo Russo G, Prelaj A, et al. ALK/ROS1 rearrangements: a real hallmark for thromboembolic events in cancer patients? Thromb Res. 2020;194:176–177.
   PubMed Web of Science ®Google Scholar
• Spencer SA, Riley AC, Matthew A, et al. Brigatinib: novel ALK inhibitor for non-small-cell lung cancer. Ann Pharmacother. 2019;53:621–626.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Huang T-Q, Nepliouev I, et al. crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity. Cardio Oncol. 2017;3(1):1–8
   PubMedGoogle Scholar
• Shopp GM, Helson L, Bouchard A, et al. Liposomes ameliorate crizotinib- and nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation. Anticancer Res. 2014;34:4733–4740.
   PubMed Web of Science ®Google Scholar
• Doherty KR, Wappel RL, Talbert DR, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013;272:245–255.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang W, Wu F, et al. High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations. Transl Lung Cancer Res. 2021;10:1512–1524.
   PubMed Web of Science ®Google Scholar
• Tartarone A, Gallucci G, Lazzari C, et al. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. Future Oncol. 2015;11:2043–2048.
   PubMed Web of Science ®Google Scholar